| abstract |
The compounds of formula (I) are useful as inhibitors of metalloproteases. They may be used in the treatment of diseases, disorders and conditions characterized by metalloprotease activity, for example arthritis, cancer and ocular disorders. In formula (I): R1 is H; R2 is hydrogen, alkyl, or acyl; A is COR3 or S02R4; where R3 is alkoxy, aryloxy, heteroaryloxy, alkyl, aryl, heteroaryl, heteroalkyl, amino, alkylamino, dialkylamino, arylamino and alkylarylamino; and R4 is independently alkyl, heteroalkyl, aryl, or heteroaryl, substituted or unsubstituted; X is O, S, SO, SO2, or NR5, wherein R5 is chosen from hydrogen, alkyl, heteroalkyl, heteroaryl, aryl, S02R6, COR7, CSR8, PO(R9)2, or may optionally form a ring with Y or W; R6 is independently alkyl, aryl, heteroaryl, heteroalkyl, amino, alkylamino, dialkylamino, arylamino, diarylamino and alkylarylamino; R7 is independently hydrogen, alkoxy, aryloxy, heteroaryloxy, alkyl, aryl, heteroaryl, heteroalkyl, amino, alkylamino, dialkylamino, arylamino and alkylarylamino; R8 is independently alkyl, aryl, heteroaryl, heteroalkyl, amino, alkylamino, dialkylamino, arylamino, diarylamino or alkylarylamino; and R9 is independently alkyl, aryl, heteroaryl or heteroalkyl; W is independently one or more of hydrogen or lower alkyl, or a heterocycle, or is an alkylene, arylene or heteroarylene bridge between two adjacent or nonadjacent carbons (thus forming a fused ring); Y is independently one or more of hydrogen, hydroxy, SR10, SOR4, SO2R4, alkoxy or amino, wherein amino is of formula NR11R12, where R11 and R12 are independently chosen from hydrogen, alkyl, heteroalkyl, heteroaryl, aryl, SO2R6, COR7, CSR8, PO(R9)2; and R10 is independently hydrogen, alkyl, aryl or heteroaryl; Z is nil, a spiro moiety or an oxo group substituted on the heterocyclic ring; and n is 1-4. |